Irene Wapnir

Clinical Trials

• Recruiting SPY Intra-Operative Angiography & Skin Perfusion in Immediate Breast Reconstruction w/ Implants
• Not Recruiting Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
• Not Recruiting Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
• Recruiting Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
• Not Recruiting Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
• Recruiting Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample
• Recruiting Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
• Not Recruiting Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
• Not Recruiting A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
• Not Recruiting Phase II Anastrozole and ZD6474 in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
• Not Recruiting A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
• Not Recruiting Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
• Recruiting Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
• Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
• Recruiting Pilot Indocyanine Green™ Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer
• Not Recruiting Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers
• Not Recruiting Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
• Not Recruiting BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
• Not Recruiting Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas
• Not Recruiting Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
• Not Recruiting Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study
• Not Recruiting Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer
• Not Recruiting Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT
• Not Recruiting Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer
• Recruiting Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer